Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
Mattia Garutti, Giada Targato, Silvia Buriolla, et al.
Cells (2021) Vol. 10, Iss. 6, pp. 1334-1334
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma
Inger Z. M. Kreuger, Roderick C. Slieker, Tim van Groningen, et al.
Journal of Investigative Dermatology (2022) Vol. 143, Iss. 1, pp. 18-25.e1
Open Access | Times Cited: 41
CDK4/6 inhibitors in lung cancer: current practice and future directions
Shuoshuo Lv, Jie Yang, Jiayuh Lin, et al.
European Respiratory Review (2024) Vol. 33, Iss. 171, pp. 230145-230145
Open Access | Times Cited: 10
Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
Tina Jost, Lucie Heinzerling, Rainer Fietkau, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 50
Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
Taylor Rager, Adam Eckburg, Meet Patel, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3779-3779
Open Access | Times Cited: 31
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER + breast cancer with mitotic aberrations
Isabel Soria‐Bretones, Kelsie L. Thu, Jennifer Silvester, et al.
Science Advances (2022) Vol. 8, Iss. 36
Open Access | Times Cited: 30
The Genomic Landscape of Melanoma and Its Therapeutic Implications
Ting‐Ting Yang, Sebastian Yu, Chiao‐Li Khale Ke, et al.
Genes (2023) Vol. 14, Iss. 5, pp. 1021-1021
Open Access | Times Cited: 17
Advances in Melanoma: From Genetic Insights to Therapeutic Innovations
Fernando Valdez-Salazar, Luis Alberto Jiménez-Del Río, Jorge Ramón Padilla‐Gutiérrez, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1851-1851
Open Access | Times Cited: 7
Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways
Songyu Shen, Yihan Hong, Jiajun Huang, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 16-28
Closed Access | Times Cited: 6
Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors
Alexander Bang, Christopher J. Fay, Nicole R. LeBoeuf, et al.
Breast Cancer Research and Treatment (2024) Vol. 204, Iss. 3, pp. 643-647
Closed Access | Times Cited: 5
Development of Personalized Strategies for Precisely Battling Malignant Melanoma
Armond J. Isaak, G Clements, Rand Gabriel M. Buenaventura, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 5
Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells
Karunakar Saamarthy, Kristofer Ahlqvist, Renée Daams, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
β‐Galactosidase‐Triggered Photodynamic Elimination of Senescent Cells with a Boron Dipyrromethene‐Based Photosensitizer
Jacky C. H. Chu, Blanca Escriche‐Navarro, Junlong Xiong, et al.
Advanced Science (2024) Vol. 11, Iss. 31
Open Access | Times Cited: 4
Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management
Soo Hyun Kim, Hensin Tsao
Biomolecules (2025) Vol. 15, Iss. 1, pp. 120-120
Open Access
Diagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis
Haniyeh Rafiepoor, Alireza Ghorbankhanloo, Soroush Soleimani Dorcheh, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 2
Open Access
Arcyriaflavin A, a cyclin D1/CDK4 inhibitor, suppresses tumor growth, migration, and invasion of metastatic melanoma cells
Dokyeong Kim, Junseong Park, Yoon‐Seob Kim, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Cell Death Modalities in Therapy of Melanoma
Meng Wang, Jiahui Zhao, Ming Tang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3475-3475
Open Access
Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
Karam Khaddour, Lucas Maahs, Ana Maria Avila-Rodriguez, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5847-5847
Open Access | Times Cited: 27
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
Kelsey W. Nassar, Jennifer D. Hintzsche, Stacey M. Bagby, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 10, pp. 2049-2060
Open Access | Times Cited: 25
Treatment of acral and mucosal melanoma: Current and emerging targeted therapies
Jiaran Zhang, Huichun Tian, Lili Mao, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104221-104221
Closed Access | Times Cited: 10
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 5, pp. 1174-1188
Open Access | Times Cited: 3
Targeted Therapy for Melanomas Without BRAF V600 Mutations
Christian Menzer, Jessica C. Hassel
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 6, pp. 831-842
Open Access | Times Cited: 16
CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes
Anastasiia Danishevich, Airat Bilyalov, Sergey Nikolaev, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3343-3343
Open Access | Times Cited: 9
Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response
Tijana Randic, Stefano Magni, Demetra Philippidou, et al.
Cell Reports (2023) Vol. 42, Iss. 7, pp. 112696-112696
Open Access | Times Cited: 8
Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors
Vivek Gupta, Vishakha Vashisht, Ashutosh Vashisht, et al.
Genes (2024) Vol. 15, Iss. 4, pp. 396-396
Open Access | Times Cited: 2
Synthesis and Preclinical Evaluation of Novel 68Ga-DOTA-RBB as Potential PET Radiotracer for Imaging CDK4/6 in Tumors
Zhen-Peng Yu, Xin Wang, Zhiqiang Yu, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 6, pp. 938-944
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top